share_log

bluebird bio | 3: Initial statement of beneficial ownership of securities-Director Cloonan Michael

SEC announcement ·  Jun 25 05:16
Summary by Futu AI
Michael Cloonan, a director and 10% owner of bluebird bio, Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per a Form 3 submission dated 06/20/2024. The document, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that Cloonan does not beneficially own any non-derivative or derivative securities of the company. The form, signed by attorney-in-fact Sydney Gaylin on 06/24/2024, confirms the reporting person's beneficial ownership status and is a standard procedure for individuals in certain positions within publicly traded companies.
Michael Cloonan, a director and 10% owner of bluebird bio, Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per a Form 3 submission dated 06/20/2024. The document, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that Cloonan does not beneficially own any non-derivative or derivative securities of the company. The form, signed by attorney-in-fact Sydney Gaylin on 06/24/2024, confirms the reporting person's beneficial ownership status and is a standard procedure for individuals in certain positions within publicly traded companies.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.